Cardax, Inc.
CDXI - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$80
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $80.00 |
|---|---|
| Enterprise Value | $5.34 Million |
| Earnings per Share | $-6.79 |
| Beta | -2.98 |
| Outstanding Shares | 794,183 |
Return
| Return on Equity | 67.67% |
|---|---|
| Return on Assets | -557.32% |
| Return on Invested Capital | 27.64% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 10.66 |
| Enterprise Value to EBIT | -1.74 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.01 |
| Debt to Equity | -0.48 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Cardax, Inc.
10 employees
CEO: David G. Watumull
Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and marketing nutritional supplements for maintaining inflammatory well-being, as well as developing pharmaceutical treatments for chronic ailments rooted in inflamm...